Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China

Xin-yu JI; Yan MA; Shuai SHI; Si-hong LIU; Lin TONG; Cheng LYU; Hua-min ZHANG; Yan-ping WANG

doi:10.1007/s11655-021-2880-1

Your Location：

Home >

Browse articles >

Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China

Original Article | Updated：2022-09-08

- Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China
- Chinese Journal of Integrative Medicine Vol. 28, Issue 9, Pages: 779-784(2022)
- Affiliations：
  
  1.Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing (100700), China
  2.Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing (100053), China
  3.Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, Beijing (100700), China
  4.Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing (100700), China
- Author bio：
  
  Prof. WANG Yan-ping, E-mail:wangyanping4816@163.com
- Funds：
- DOI：10.1007/s11655-021-2880-1
  CLC：
- Published：2022-09，
  
  Published Online：13 January 2022，
  
  Accepted：28 August 2020
Scan for full text
Xin-yu JI, Yan MA, Shuai SHI, et al. Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China. [J]. Chinese Journal of Integrative Medicine 28(9):779-784(2022)
DOI：

Xin-yu JI, Yan MA, Shuai SHI, et al. Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China. [J]. Chinese Journal of Integrative Medicine 28(9):779-784(2022) DOI： 10.1007/s11655-021-2880-1.

摘要

目的:

总结中医药防治新型冠状病毒肺炎 (以下简称“新冠肺炎”) 诊疗方案的用药规律

为临床诊治提供参考.

方法:

搜索从2019年12月8日到2020年3月10日的各省市政府网站和官方媒体网站上的中医药防治新冠肺炎诊疗方案. 分防治阶段和地区对诊疗方案的中药组方进行用药频次、中药配伍、聚类以及复杂网络分析等.

结果:

在27个中医诊治方案中

治疗处方共有203个

用药频次较高的前4位中药分别为: 甘草、杏仁、麻黄、藿香

核心组合是麻黄和杏仁. 在48个预防处方中

使用频率最高的中药分别为: 黄芪、甘草、防风、金银花等. 核心配伍处方为黄芪、甘草、防风

是玉平风散的主要成分. 中国华东地区的诊疗方案中

防治处方共45个

使用频率最多的中药是甘草、藿香、陈皮和石膏等. 中国华北地区的诊疗方案中

防治处方共50个

使用频率最多的中药是藿香、杏仁、麻黄和茯苓等.

结论:

在预防新冠肺炎方面

中医药主要侧重于提高人体免疫力; 治疗上

则重在清肺利湿. 中药处方的应用因地制宜

可能是由于气候和环境的差异

这些结果有助于临床医生快速制定中医药诊疗计划.

Abstract

Objectives:

To summarize the measures and rules of Chinese medicine (CM) and provide reference for clinical application in the prevention and treatment of coronavirus disease (COVID-19).

Methods:

The data source was from CM COVID-19 prevention and treatment programs on government websites and official media websites of the different provinces and cities. The search lasted from December 8

2019 to March 10

2020. Main variables were medication frequency and combinations of medicines. Cluster analysis and complex network analysis were used by prevention and treatment stage and by area.

Results:

Among 27 CM diagnosis and treatment plans

203 therapeutic prescriptions were enrolled

of which the top 4 herbs were:

Radix glycyrrhizae

Semen armeniacae amarum

Herba ephedrae

and

Herba agastachis

respectively. The core combinations were

Herba ephedrae

and

Semen armeniacae amarum

. Forty-eight preventive formulae were identified. Ten herbs

including

Radix Astragali seu hedysari

Radix glycyrrhizae

Radix saposhnikoviae

Flos lonicerae

etc. were most frequently used. The core prescription of CM compatibility was

Radix astragali seu hedysari

Radix glycyrrhizae

and

Radix saposhnikoviae

which is the main component of Yu Ping Feng San. There were 45 prevention and treatment prescriptions in East China; the most used CM was

Radix glycyrrhizae

Herba agastachis

Pericarpium citri reticulatae

and

Gypsum fibrosum

. Fifty prescriptions were identified in North China. According to CM analyses

Herba agastachis

Semen armeniacae amarum

Herba ephedrae

and

Poria

were most frequently used.

Conclusions:

CM for COVID-19 prevention mainly focuses on improving human immunity; for treatment

prescription focuses on clearing the lungs and removing dampness. Prescriptions vary with regions

perhaps due to climatic and environmental differences

which help clinicians to quickly make CM plans and treat patients according to clinical status

further minimizing resource wastage.

关键词

COVID-19中药用药规律

Keywords

COVID-19Chinese medicineregularity of medication

references

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020;395:470-473.

WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed on 24 March 2020.

Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Rev Med Discovery 2020;19:149-150.

Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Gu L, et al.Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med 2011;155:217-225.

Hsu CH, Hwang KC, Chao CL, Chang SG, Ho MS, Chou P. Can herbal medicine assist against avian flu? Learning from the experience of using supplementary treatment with Chinese medicine on SARS or SARS-like infectious disease in 2003. J Altern Complement Med 2006;12:505-506.

Yang Y, Islam MS, Wang J, Li Y, Chen X. Traditional Chinese medicine in the treatment of patients infected with 2019-novel coronavirus (SARS-CoV-2): a review and perspective. Int J Biol Sci 2020;16:1708-1717.

Huang Z, Fu F, Ye H, Gao H, Tan B, Wang R, et al.Chinese herbal Huo-Gu Formula for treatment of steroid-associated osteonecrosis of femoral head: a 14-years follow-up of convalescent SARS patients. J Orthop Trans 2020. doi: 10.1016/j.jothttp://doi.org/10.1016/j.jot. [Epub ahead of print]

General Office of the State Health Committee, State Administration of Traditional Chinese Medicine Office. Notice of the State on Printing and Distributing the Diagnosis and Treatment Plan of COVID-19 (Trial 7th edition) (EB/OL).(2020-03-03). Http://www.nhc.gov.cn/yzygj/s7653p/202003/4 6c9294a7dfe4cef80dc7f5912eb1989.ShtmlHttp://www.nhc.gov.cn/yzygj/s7653p/202003/4 6c9294a7dfe4cef80dc7f5912eb1989.Shtml.

State Council Information Office. State novel Office Held Press Conference: Yu Yanhong Introduced the Important Role of Traditional Chinese Medicine in Participating in COVID-19 Prevention and Treatment (EB/OL). (2020-03-27).http://ghs.saCM.gov.cn/gongzuodongtai/2020-03-27/14\http://ghs.saCM.gov.cn/gongzuodongtai/2020-03-27/14\

Xinhua net. The first Chinese medicine mobile cabin hospital in Wuhan was put into operation.(EB/OL).http://www.xinhuanet.com/politics/2020-02/14/c_1125576187.htmhttp://www.xinhuanet.com/politics/2020-02/14/c_1125576187.htm,2020-2-14.

State Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China: Part Ⅰ. Beijing: China Pharmaceutical Science and Technology Press; 2015:1-1750.

Nanjing University of Traditional Chinese Medicine. Dictionary of Traditional Chinese Medicine. 2nd ed. Shanghai: Shanghai Science and Technology Press; 2006:1-2094.

Gao XM. Chinese medicine. Beijing: Chinese Medicine Press; 2002:1-631.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China(J/OL). (2020-02-13). JAMA 2020. https://jamanetwork.com/journals/jama/fullarticle/2761044https://jamanetwork.com/journals/jama/fullarticle/2761044.

Fan YP, Wang YP, Zhang HM, Wang YY. Analysis on treatment of novel coronavirus pneumonia from cold disease. J Tradit Chin Med (Chin) 2020;61:369-374.

Xue BS, Yao KW, Xue YX. Traditional Chinese medicine theory analysis of "Qingfei Paidu Decoction" for rapid and effective treatment of novel coronavirus pneumonia. J Tradit Chin Med (Chin) 2020;61:461-462.

Fan YP, Wang YP, Ma Y, Zhao C, Zhang HM. Analysis on composition mechanism of Qingfei Paidu Tang from pathogenesis of cold pestilence of COVID-19 (J/OL). Chin J Exp Tradit Med Formulae (Chin):1-4(2020-04-10). https://doi-org-s.vpn.ccmu.edu.cn/10.13422/j.cnki.syfjx.20201157https://doi-org-s.vpn.ccmu.edu.cn/10.13422/j.cnki.syfjx.20201157.

Tong XL, Li XY, Zhao LH, Li QW, Yang YY, Lin YQ, et al.Exploration of TCM prevention and treatment strategies of novel coronavirus pneumonia from the perspective of "cold-damp epidemic". J Tradit Chin Med (Chin) 2020;61:465-470, 553.

Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H,Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.Lancet 2003;361:2045-2046.

Du HK, Song FW, Zhou X, Li H, Zhang JP. Effect of amygdlin on type Ⅰ and Ⅲ collagen expression in rats with pulmonary fibrosis induced by bleomycin. J Chin PLA Postgrad Med Sch (Chin) 2009;30:712-714+717.

Gao XL, Xiong S, Wang YF, Wang XY, Zhang MY, Yuan YQ, et al. Preliminary study on the anti-coxsackievirus B3 effect of three effective parts of patchouli in vitro. Tradit Chin Med Mater (Chin) 2009;32:761-764.

Wei XL, Peng C, Wan F. Study on the anti-respiratory virus effect of Patchool in vitro. Pharmacol Clin Chin Mater Med(Chin) 2013;29:26-29.

Peng SZ, Li G, Qin Z, Su ZR, Zhang FX, Lai XP. Effect of different extract parts of Pogostemon cablin (Blanco) Benth on in vivo anti-influenza virus. Lishizhen Med Mater Med Res (Chin) 2011;22:2578-2579.

Wang C, Cao B, Liu QQ, Zou ZQ, Liang ZA, Li G, et al.Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza:a randomized trial. Ann Intern Med 2011;155:217-225.

Liu P, Zhao HP, Luo YM. Anti-aging implications of Astragalus Membranaceus (Huangqi): a well-known Chinese tonic. Aging Dis 2017;8:868-886.

Li YK, Li W, Fu CM, Song Y, Fu Q. Lonicerae Japonicae Flos and Lonicerae Flos: a systematic review of ethnopharmacology, phytochemistry and pharmacology.Phytochem Rev 2019;22:1-61.

Du CY, Choi RC, Zheng KY, Dong TT, Lau DT, Tsim KW.Yu Ping Feng San, an ancient Chinese herbal decoction containing Astragali Radix, Atractylodis Macrocephalae Rhizoma and Saposhnikoviae Radix, regulates the release of cytokines in murine macrophages. PLoS One 2013;8:e78622.

Li YC, Zhang W. Inheritance and exertion of the thought of "Three Factors and Conditions" in the Yellow Emperor's Inner Canon by Shi Bing Lun. Chin J Basic Med Tradit Chin Med (Chin) 2017;23:31-32.

Huang LL, Wang JA, Wei Q. Analysis on the law of traditional Chinese medicine for the prevention and treatment of novel corona (J/OL). Chin Med Herbs:1-11(2020-04-21).http://wfs.sxsrsc.com:8000/rwt/CNKI/http/NNYHGLUDN3WXTLUPMW4A/kcms/detail/44.1286.R.20200327.1416.002.htmlhttp://wfs.sxsrsc.com:8000/rwt/CNKI/http/NNYHGLUDN3WXTLUPMW4A/kcms/detail/44.1286.R.20200327.1416.002.html.

Du S, Peng X, Li F, Yu Z. Analysis on syndrome differentiation and typing of epidemic Japanese encephalitis treated by traditional Chinese medicine in 60 years. Chin J Basic Med Tradit Chin Med (Chin) 2017;23:31-32.

Jiang D, Zhuo QY, Chen XM, Hu J. Enlightenment of diagnosis and treatment of SARS in Beijing and Guangzhou.Lishizhen Med Mater Med Res (Chin) 2017;28:1167-1169.

Bai AJ, Liu XD. Variation characteristics of precipitation in Eastern China in recent 50 years and its relation with drought and flood disasters. J Trop Meteorol (Chin)2010;26:194-200.

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effectiveness of Acupoint Application in Patients with Pharyngeal Pain: Evidence from CHUNBO,A Prospective Real-World Study

Danhong Injection Up-Regulates miR-125b in Endothelial Exosomes and Attenuates Apoptosis in Post-Infarction Myocardium

Retrospective Clinical Study on Integrated Chinese and Western Medicine in Treatment of Limited-Stage Small-Cell Lung Cancer

Challenges and Perspectives in Target Identification and Mechanism Illustration for Chinese Medicine^*

Active Ingredients of Reduning Injection Maintain High Potency against SARS-CoV-2 Variants

Related Author

No data

Related Institution

Postdoctoral Workstation of Yabao Pharmaceutical Group Co., Ltd.

National Clinical Research Center for Chinese Medicine Cardiology

National Medical Products Administration for Laboratory of Clinical Research and Evaluation of Traditional Chinese Medicine

Emergency Department, Xiyuan Hospital Affiliated to China Academy of Chinese Medical Sciences

Beijing Institute of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰